{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:56:32Z","timestamp":1793876192447,"version":"4.7.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":119,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Type 2 diabetes (T2D) is the leading cause of chronic kidney disease (CKD) and kidney failure globally. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, reduces the risk of major kidney, cardiovascular and mortality outcomes in people with T2D and CKD, but the mechanism of action remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The REMODEL trial (NCT04865770) is a 52-week placebo-controlled, double-blind, parallel-group, randomized trial in adults with T2D and CKD. Inclusion criteria include haemoglobin A1c (HbA1c) \u22649%, estimated glomerular filtration rate (eGFR) \u226530\u2013\u226475\u00a0ml\/min\/1.73\u00a0m2 and urine albumin:creatinine ratio (UACR) \u226520\u2013&amp;lt;5000\u00a0mg\/g. The co-primary outcomes were magnetic resonance imaging (MRI) based, including change in kidney oxygenation, perfusion and inflammation. Secondary outcomes include change from baseline in creatine clearance rate, urinary sodium excretion, albumin excretion rate and kidney fibrosis and blood flow parameters measured by MRI. A subgroup had kidney biopsies at baseline and at the end of the treatment for tissue-based interrogation, including single nucleus and spatial transcriptomics, pathology and advanced histological assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across eight countries, 106 participants (n\u00a0=\u00a033, biopsy subgroup) were enrolled. The mean age was 65.3\u00a0years [standard deviation (SD) 9.9] at baseline with HbA1c of 7.1% (SD 0.9), creatinine-based eGFR of 51.1\u00a0ml\/min\/1.73\u00a0m2 (SD 10.4) and median UACR of 187.3\u00a0mg\/g (interquartile range 60.5\u2013546.4). Renin\u2013angiotensin system inhibitor use was 98.1% and sodium\u2013glucose co-transporter 2 inhibitor use was 38.7%. In the kidney biopsy subgroup, baseline characteristics were like those of the full population. Histological analysis of kidney tissues revealed 17 participants with primarily diabetic nephropathy, 6 participants with primarily vascular features, 9 with mixed diabetic nephropathy and vascular characteristics and 1 with membranous nephropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The REMODEL trial leverages multipronged approaches to investigate the kidney-specific effects and underlying mechanisms of semaglutide in a representative population of people with T2D and CKD, which supports the generalizability and clinical relevance of the findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf114","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T08:04:32Z","timestamp":1751443472000},"page":"2182-2192","source":"Crossref","is-referenced-by-count":23,"title":["Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease"],"prefix":"10.1093","volume":"40","author":[{"given":"David Z I","family":"Cherney","sequence":"first","affiliation":[{"name":"University Health Network Department of Medicine, Division of Nephrology, , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Belmar","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Bjornstad","sequence":"additional","affiliation":[{"name":"University of Washington Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, and Division of Endocrinology, Department of Pediatrics, , Seattle, WA ,","place":["USA"]},{"name":"University of Colorado Anschutz Medical Campus Division of Renal Diseases and Hypertension, Department of Medicine, Section of Pediatric Endocrinology, Department of Pediatrics, , Aurora, CO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milenta M","family":"Chacko","sequence":"additional","affiliation":[{"name":"Novo Nordisk GBS India , Bangalore ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P","family":"Gunnarsson","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B","family":"Hodgin","sequence":"additional","affiliation":[{"name":"University of Michigan Department of Pathology and Clinical Laboratories, , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kretzler","sequence":"additional","affiliation":[{"name":"University of Michigan Department of Internal Medicine and Bioinformatics, , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1027-1851","authenticated-orcid":false,"given":"Menno","family":"Pruijm","sequence":"additional","affiliation":[{"name":"Service of Nephrology, University Hospital of Lausanne and University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A","family":"Schytz","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2235-0103","authenticated-orcid":false,"given":"Katherine R","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Providence Medical Research Center, Providence Inland Northwest Health , Spokane WA ,","place":["USA"]},{"name":"Kidney Research Institute and Nephrology Division, University of Washington School of Medicine , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"2025102920024346700_bib1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41581-020-0268-7","article-title":"The impact of chronic kidney disease on global health","volume":"16","author":"Carney","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2025102920024346700_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","journal-title":"Lancet"},{"key":"2025102920024346700_bib3","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102920024346700_bib4","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.2215\/CJN.03700417","article-title":"Diabetes and CKD in the United States population, 2009\u20132014","volume":"12","author":"Zelnick","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025102920024346700_bib5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1053\/j.ackd.2014.03.003","article-title":"Cardiovascular complications of diabetic kidney disease","volume":"21","author":"P\u00e1lsson","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"2025102920024346700_bib6","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"2025102920024346700_bib7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12933-023-01937-x","article-title":"The cardio-renal-metabolic connection: a review of the evidence","volume":"22","author":"Marassi","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2025102920024346700_bib8","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/jep.12960","article-title":"The use of mechanistic evidence in drug approval","volume":"24","author":"Aronson","year":"2018","journal-title":"Eval Clin Pract"},{"issue":"4 Suppl","key":"2025102920024346700_bib9","first-page":"S117","article-title":". KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"issue":"5 Suppl","key":"2025102920024346700_bib10","first-page":"S1","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes Diabetes Work Group","year":"2022","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"2025102920024346700_bib11","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.2337\/dc25-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes\u20132025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2025102920024346700_bib12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MNH.0000000000000894","article-title":"Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease","volume":"32","author":"Alicic","year":"2023","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2025102920024346700_bib13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2025102920024346700_bib14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025102920024346700_bib15","first-page":"102","article-title":"Renoprotection with semaglutide and liraglutide: direct or indirect effects? [abstract]","volume":"30","author":"Mann","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2025102920024346700_bib16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2025102920024346700_bib17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12933-022-01585-7","article-title":"Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials","volume":"21","author":"Mosenzon","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2025102920024346700_bib18","doi-asserted-by":"publisher","first-page":"F443","DOI":"10.1152\/ajprenal.00280.2019","article-title":"Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation","volume":"318","author":"Hviid","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025102920024346700_bib19","doi-asserted-by":"publisher","first-page":"706908","DOI":"10.3389\/fphar.2021.706908","article-title":"GLP-1 receptor: a new target for sepsis","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025102920024346700_bib20","doi-asserted-by":"publisher","first-page":"F734","DOI":"10.1152\/ajprenal.00454.2010","article-title":"Infiltrating T lymphocytes in the kidney increase oxidative stress and participate in the development of hypertension and renal disease","volume":"300","author":"De Miguel","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025102920024346700_bib21","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ajpath.2019.10.008","article-title":"Glucagon-like peptide-1 receptor agonism improves nephrotoxic serum nephritis by inhibiting T-cell proliferation","volume":"190","author":"Moschovaki Filippidou","year":"2020","journal-title":"Am J Pathol"},{"key":"2025102920024346700_bib22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","article-title":"Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation","volume":"105","author":"Sourris","year":"2024","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"2025102920024346700_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2337\/db24-6-OR","article-title":"Renal cell type-associated therapeutic effects of semaglutide in a mouse model of hypertension-accelerated diabetic kidney disease","volume":"73","author":"Tozzi","year":"2024","journal-title":"Diabetes"},{"key":"2025102920024346700_bib24","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"2025102920024346700_bib25","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE\u2212\/\u2212 and LDLr\u2212\/\u2212 mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"2025102920024346700_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/medicina55060233","article-title":"GLP-1 receptor agonists and kidney protection","volume":"55","author":"Greco","year":"2019","journal-title":"Medicina (Kaunas)"},{"key":"2025102920024346700_bib27","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1096\/fj.201601116R","article-title":"Critical role of the cAMP-PKA pathway in hyperglycemia-induced epigenetic activation of fibrogenic program in the kidney","volume":"31","author":"Deb","year":"2017","journal-title":"FASEB J"},{"key":"2025102920024346700_bib28","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/ki.2013.427","article-title":"The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential","volume":"85","author":"Fujita","year":"2014","journal-title":"Kidney Int"},{"key":"2025102920024346700_bib29","doi-asserted-by":"publisher","first-page":"e027712","DOI":"10.1161\/JAHA.122.027712","article-title":"GLP-1 promotes cortical and medullary perfusion in the human kidney and maintains renal oxygenation during NaCl loading","volume":"12","author":"Haddock","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2025102920024346700_bib30","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1210\/jc.2019-00004","article-title":"Extracellular fluid volume expansion uncovers a natriuretic action of GLP-1: a functional GLP-1-renal axis in man","volume":"104","author":"Asmar","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2025102920024346700_bib31","first-page":"667","article-title":"Blood oxygenation level-dependent MRI to assess renal oxygenation in renal diseases: progresses and challenges","volume":"7","author":"Pruijm","year":"2016","journal-title":"Front Physiol"},{"key":"2025102920024346700_bib32","doi-asserted-by":"publisher","first-page":"e164486","DOI":"10.1172\/JCI164486","article-title":"SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth-onset type 2 diabetes","volume":"133","author":"Schaub","year":"2023","journal-title":"J Clin Invest"},{"key":"2025102920024346700_bib33","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2025102920024346700_bib34","doi-asserted-by":"publisher","first-page":"17528","DOI":"10.1038\/s41598-024-68406-7","article-title":"Investigating quantitative histological characteristics in renal pathology using","volume":"14","author":"Border","year":"2024","journal-title":"Sci Rep"},{"key":"2025102920024346700_bib35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2818.1979.tb00149.x","article-title":"Determination of membrane thickness distribution from orthogonal intercepts","volume":"115","author":"Jensen","year":"1979","journal-title":"J Microsc"},{"key":"2025102920024346700_bib36","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1097\/TP.0000000000002366","article-title":"A 2018 reference guide to the Banff classification of renal allograft pathology","volume":"102","author":"Roufosse","year":"2018","journal-title":"Transplantation"},{"key":"2025102920024346700_bib37","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1053\/ajkd.2002.31988","article-title":"Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies","volume":"39","author":"Mazzucco","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2025102920024346700_bib38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1148\/rg.2020190039","article-title":"Phase-contrast MRI: physics, techniques, and clinical applications","volume":"40","author":"Wymer","year":"2020","journal-title":"Radiographics"},{"key":"2025102920024346700_bib39","doi-asserted-by":"publisher","first-page":"ii4","DOI":"10.1093\/ndt\/gfy152","article-title":"Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European cooperation in science and technology action PARENCHIMA","volume":"33","author":"Selby","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2025102920024346700_bib40","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2025102920024346700_bib41","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"2025102920024346700_bib42","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc24-S006","article-title":"6. Glycemic goals and hypoglycemia: standards of care in diabetes\u20142024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"2025102920024346700_bib43","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2025102920024346700_bib44","doi-asserted-by":"publisher","first-page":"sfad266","DOI":"10.1093\/ckj\/sfad266","article-title":"Should we enlarge the indication for kidney biopsy in patients with diabetes? The pro part","volume":"17","author":"Gesualdo","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025102920024346700_bib45","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41581-021-00462-y","article-title":"Trajectories of kidney function in diabetes: a clinicopathological update","volume":"17","author":"Oshima","year":"2021","journal-title":"Nat Rev Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf114\/63661180\/gfaf114.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/11\/2182\/65001811\/gfaf114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/11\/2182\/65001811\/gfaf114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:02:52Z","timestamp":1761782572000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/11\/2182\/8185402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,7,3]]},"published-print":{"date-parts":[[2025,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf114","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,7,3]]}}}